Top story
AbbVie Closes $10.9B Apogee Deal — Zumilokibart's Phase 3 Will Decide Whether ABBV Investors Paid a Fair Price
AbbVie closed its $10.9B Apogee deal Sept 3. Core asset: zumilokibart, IL-13 antibody twice-yearly vs Dupixent's bi-weekly shots. EPS dilution through 2031; accretion in 2032.
LineVest Daily
Get this wrap in your inbox every morning.
One email before the U.S. open — the earnings, filings, and guidance changes that matter, in plain English. Free.
Subscribe free